Clinical Trials Logo

Posttraumatic Stress Disorder clinical trials

View clinical trials related to Posttraumatic Stress Disorder.

Filter by:

NCT ID: NCT01263067 Completed - Clinical trials for Posttraumatic Stress Disorder

Lifespan Integration for Posttraumatic Stress Disorder From an Auto Accident

Start date: October 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate if lifespan integration (LI) therapy reduces posttraumatic stress symptoms following a motor vehicle accident (MVA) trauma

NCT ID: NCT01259921 Completed - Clinical trials for Posttraumatic Stress Disorder

EEG Biofeedback in the Treatment of Chronic Treatment-Resistant PTSD

Start date: December 2009
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether neurofeedback (NF) training can significantly reduce the symptoms of Posttraumatic Stress Disorder (PTSD) in individuals with significant affect dysregulation and chronic, treatment-resistant PTSD. The primary aims of this study include: 1. To examine whether NF has the potential to significantly reduce symptoms of PTSD. 2. To examine whether NF training can specifically target the area of affect regulation. 3. To examine the mechanism of NF through elucidating the relationship between affect regulation and PTSD symptom change.

NCT ID: NCT01211405 Completed - Clinical trials for Posttraumatic Stress Disorder

Study Comparing Three Doses of MDMA Along With Therapy in Veterans With Posttraumatic Stress Disorder

Start date: November 10, 2010
Phase: Phase 2
Study type: Interventional

This study is designed to provide information on whether therapy ("talk therapy") combined with the drug MDMA is safe and helpful for subjects with posttraumatic stress disorder (PTSD). The study will compare the effects of a low, a medium and a full dose of MDMA on symptoms of PTSD in 24 veterans, firefighters or police officers. MDMA dose will be assigned at random, and the investigators and the subject will not know the dose given. The researchers will also investigate depression symptoms. The researchers believe that the full dose of MDMA will produce a greater reduction in PTSD symptoms than the two lower doses.

NCT ID: NCT01196624 Completed - Clinical trials for Posttraumatic Stress Disorder

Repetitive Transcranial Magnetic Stimulation With Or Without Traumatic Stimuli in Post Traumatic Stress Disorder (PTSD)

BSPTSDTMS2010
Start date: November 2008
Phase: Phase 2
Study type: Interventional

Subjects Forty consecutive patients fulfilling the DSM-IV diagnostic criteria for PTSD will be recruited from the inpatient and outpatient treatment programs at the Beer Sheva Mental Health Center. Patients will complet a course of 10 daily rTMS sessions. After receiving a full explanation of the procedures, all subjects will sign a written informed consent statement approved by the Helsinki Ethics Committee of Ben-Gurion University. Study Design The study suggested here will recruit 40 patients with DSM-IV PTSD also demonstrating at least moderately severe flashbacks. Each of the subjects will be recruited randomly to one of 4 groups: 1. Right DLPF Rtms (10Hz) co-administered with neutral visual and/or auditori stimuli; 2. Right DLPF Rtms (10Hz) co-administered with visual and/or auditori traumatic stimuli mimicking experiences appearing during the patients flashbacks; 3. Left DLPF Rtms (10Hz) co-administered with neutral visual and or auditori stimuli; 4. Left DLPF Rtms (10Hz) co-administered with visual and/or auditori traumatic stimuli mimicking experiences appearing during the patients flashbacks; Treatment Characteristics rTMS will be performed with a Magstim stimulator (Magstim Company, Whitland, U.K.) The motor threshold was determined in each subject once, before treatment. This was defined as the lowest stimulation intensity capable of inducing a visible movement at least five times out of 10 stimulations. The position of the right dorsolateral prefrontal cortex will be defined as 5 cm anterior (in a parasagittal line) to the motor cortex. The stimulus intensity will be 80% of the patient's motor threshold intensity. Treatments will be given for 20 minutes per day over 10 working days. Both subjects received high-frequency rTMS) received 10 Hz for 2 seconds per train; the intertrain interval was 58 seconds. For each participant the stimulus was administered over the right dorsolateral prefrontal cortex. Rating Scales The ratings of PTSD symptoms, anxiety, and depression willm be carried out by an expert investigator who will be blind to the stimulation condition. The patients will be assessed at four time points—before TMS (baseline), at day 5, at day 10, and at day 24 (14 days after the intervention). The instruments used will be as follows: The PTSD Checklist The Treatment Outcome PTSD Scale The Hamilton Anxiety Rating Scale The Hamilton Rating Scale for Depression PTSD symptoms were assessed by using the Hebrew version of the Clinician-Administered PTSD Scale.

NCT ID: NCT01186315 Completed - Clinical trials for Posttraumatic Stress Disorder

Post-traumatic Stress Disorder (PTSD), Addiction, and Virtual Reality

Start date: December 2008
Phase: N/A
Study type: Interventional

Eligible veterans, National Guardsmen & Reservists with post-traumatic stress disorder (PTSD) and problems with addiction will be randomly assigned to one of two treatment conditions. All participants will undergo exposure therapy, a gold standard behavioral treatment for PTSD for 10 weeks. In addition to exposure therapy, some participants will be randomly assigned to receive (1) virtual reality (VR)-based exposure to cues for marijuana, cocaine, heroin, cigarette, and/or alcohol use, and (2) cellular phone-based reminders of learning (extinction reminders, or, ERs) to VR exposure (available 24 hours per day/7 days per week) to high-risk contexts for drug use. The main hypothesis is that those participants who receive exposure therapy + VR/ERs will demonstrate less substance use and lower PTSD symptoms during treatment, at post-treatment, and at follow-up than those participants who only receive exposure therapy. At study completion, a total of 123 subjects signed consent.

NCT ID: NCT01178671 Completed - Clinical trials for Posttraumatic Stress Disorder

Combined Mirtazapine and SSRI Treatment of PTSD: A Placebo-Controlled Trial

Start date: July 2010
Phase: Phase 4
Study type: Interventional

The overall goal of this study is to examine the efficacy of the combination of mirtazapine and sertraline in the treatment of posttraumatic stress disorder (PTSD). Sertraline is FDA-approved for PTSD, but it is often not fully effective. The combination of mirtazapine and serotonin reuptake inhibitors like sertraline has appeared highly effective in a related disorder -- depression. In this study, sixty patients with chronic PTSD will be randomized to treatment with either sertraline + mirtazapine or sertraline + placebo for 12 weeks. Patients who show at least a minimal response after 12 weeks will continue for another 12 weeks on the same treatment.

NCT ID: NCT01130103 Completed - Clinical trials for Posttraumatic Stress Disorder

Combination Treatment for Posttraumatic Stress Disorder (PTSD) After the World Trade Center (WTC) Attack

Start date: March 2004
Phase: Phase 4
Study type: Interventional

This randomized controlled trial evaluates efficacy of combined prolonged exposure (PE) and the selective serotonin reuptake inhibitor (SSRI) paroxetine in the treatment of survivors of the World Trade Center (WTC) attacks.

NCT ID: NCT01108146 Completed - Clinical trials for Posttraumatic Stress Disorder

Hydrocortisone in the Treatment of Intrusions in Patients With Posttraumatic Stress Disorder

Start date: October 2008
Phase: N/A
Study type: Interventional

To test overall efficacy of hydrocortisone on reexperience of traumatic memories (intrusions) and overall symptomatology in patients meeting criteria of complex chronic PTSD.

NCT ID: NCT01108133 Completed - Clinical trials for Posttraumatic Stress Disorder

Neural and Pharmacological Correlates of Intrusions in Patients With Posttraumatic Stress Disorder

Start date: October 2010
Phase: N/A
Study type: Interventional

There is evidence that glucocorticoids have an impact on intrusive memories in patients with posttraumatic stress disorder (PTSD). Hydrocortisone impairs intrusive memory retrieval whereas dexamethasone should strengthen intrusions in PTSD. We, the investigators, want to investigate (1) the effect of these two glucocorticoids on traumatic memories and (2) assess the neural correlates using the script-driven imagery paradigm in the functional magnetic resonance imaging (fMRI) scanner. We hypothesize that intrusive memories are less intensive under hydrocortisone-administration and more intense under dexamethasone-administration comparing both to a placebo-condition. Regarding the neural activation pattern we expect higher activation in the hydrocortisone condition in the amygdala, the hippocampus and the medial prefrontal cortex compared to the placebo-condition and less activation in the dexamethasone-condition compared to the placebo-condition.

NCT ID: NCT01031615 Completed - Clinical trials for Posttraumatic Stress Disorder

Evaluation of the Child and Family Traumatic Stress Intervention

CFTSI
Start date: October 2005
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the efficacy of the Child and Family Traumatic Stress Intervention (CFTSI) in preventing the development of Posttraumatic Stress Disorder (PTSD) when implemented within 30 days of a potentially traumatic event.